新型小分子类似物用于推进阿佩林受体对抗性,增强了血和微小体稳定性
Ganesh Bist1, Ahmed Elsheikh1, Sewon Kim1
1Department of Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY 14214, USA.
Bioorganic & medicinal chemistry letters
|August 10, 2025
概括
研究人员开发了新的阿佩林受体 (APJ) 抗剂,改善了癌症治疗的稳定性. 与硫酸盐相关的化合物显示出未来对抗APJ驱动癌症的药物开发的前景.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 阿佩林受体 (APJ) 是瘤学的治疗点,参与瘤生长和转移.
- 唯一已知的小分子APJ抗剂ML221具有较差的代谢稳定性,限制了其临床使用.
- 提高APJ抗体的稳定性对于开发有效的癌症疗法至关重要.
研究的目的:
- 设计和合成具有增强代谢稳定的新型APJ抗剂.
- 评估新合成的化合物的APJ抗活性和抗癌作用.
- 确定有前途的APJ对手候选人,以进一步进行体内优化.
主要方法:
- 合成含有胺,乙烯和硫酸盐连接的ML221类型.
- 在血和肝脏显微体中评估代谢稳定性.
- 通过β-arrestin抑制试验评估APJ对抗活性.
- 对APJ过度表达癌细胞和内皮细胞迁移的抗癌作用的测试.
主要成果:
- 与硫酸盐结合的类似物 (21和22) 显著改善了代谢稳定性.
- 化合物21和22保留了强大的APJ对抗活性.
- 这些类似物选择性地抑制了APJ过度表达的癌细胞,并抑制了内皮细胞迁移.
- 化合物21表现出癌细胞迁移的最强大的抑制作用.
结论:
- 硫酸盐结合是一种有利的修饰,可以增强APJ抗剂的代谢稳定性.
- 开发的类似物是代谢稳定的生物异构剂,维持APJ对抗性.
- 这些新型的APJ抗体代表了下一代癌症治疗的有希望的候选人.
相关概念视频
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.3K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.0K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.0K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
01:24Glucagon-like Receptor Agonists
418
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
418
01:25Drug-Receptor Interaction: Agonist
2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K